Prevalence of Fabry disease in patients with cryptogenic stroke:: a prospective study

被引:321
作者
Rolfs, A
Böttcher, T
Zschiesche, M
Morris, P
Winchester, B
Bauer, P
Walter, U
Mix, E
Löhr, M
Harzer, K
Strauss, U
Pahnke, J
Grossmann, A
Benecke, R
机构
[1] Univ Rostock, Dept Neurol, D-18055 Rostock, Germany
[2] Univ Rostock, Inst Diagnost & Intervent Radiol, Rostock, Germany
[3] Univ Tubingen, Dept Med Genet, Tubingen, Germany
[4] Univ Tubingen, Neurochem Lab, Tubingen, Germany
[5] Inst Child Hlth, London, England
[6] UCL, Great Ormond St Hosp Children NHS Trust, London, England
[7] Univ Mannheim Heidelberg, Dept Gastroenterol, Mannheim, Germany
[8] Univ Zurich Hosp, Dept Pathol, Inst Neuropathol, CH-8091 Zurich, Switzerland
关键词
D O I
10.1016/S0140-6736(05)67635-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Strokes are an important cause of morbidity and mortality in young adults. However, in most cases the cause of the stroke remains unclear. Anderson-Fabry disease is an X-linked recessive lysosomal storage disease resulting from the deficient alpha-galactosidase and causes an endothelial vasculopathy followed by cerebral ischaemia. To determine the importance of Fabry disease in young people with stroke, we measured the frequency of unrecognised Fabry disease in a cohort of acute stroke patients. Methods Between February, 2110, and December, 2004 721 German adults aged 18 to 55 years suffering from acute cryptogenic stroke were screened for Fabry disease. The plasma alpha-galactosidase activity in men was measured followed by sequencing of the entire alpha-GAL gene in those with low enzyme activity. By contrast, the entire alpha-GAL gene was genetically screened for mutations in women even if enzyme activity was normal. Findings 21 of 432 (4.9%) male stroke patients and seven of 2879 (2.4%) women had a biologically significant mutation within the alpha-GAL gene. The mean age of onset of symptomatic cerebrovascular disease was 38.4 years (SD 13.0) in the male stroke patients and 40.3 years (13.1) in the female group. The higher frequency of infarctions in the vertebrobasilar area correlated with more pronounced changes in the vertebrobasilar vessels like dolichoectatic pathology (42.9% vs 6.8%). Interpretation We have shown a high frequency of Fabry disease in a cohort of patients with cryptogenic stroke, which corresponds to about 1.2% in young stroke patients. Fabry disease must be considered in all cases of unexplained stroke in young patients, especially in those with the combination of infarction in the vertebrobasilar artery system and proteinuria.
引用
收藏
页码:1794 / 1796
页数:3
相关论文
共 8 条
[1]   CLASSIFICATION OF SUBTYPE OF ACUTE ISCHEMIC STROKE - DEFINITIONS FOR USE IN A MULTICENTER CLINICAL-TRIAL [J].
ADAMS, HP ;
BENDIXEN, BH ;
KAPPELLE, LJ ;
BILLER, J ;
LOVE, BB ;
GORDON, DL ;
MARSH, EE ;
KASE, CS ;
WOLF, PA ;
BABIKIAN, VL ;
LICATAGEHR, EE ;
ALLEN, N ;
BRASS, LM ;
FAYAD, PB ;
PAVALKIS, FJ ;
WEINBERGER, JM ;
TUHRIM, S ;
RUDOLPH, SH ;
HOROWITZ, DR ;
BITTON, A ;
MOHR, JP ;
SACCO, RL ;
CLAVIJO, M ;
ROSENBAUM, DM ;
SPARR, SA ;
KATZ, P ;
KLONOWSKI, E ;
CULEBRAS, A ;
CAREY, G ;
MARTIR, NI ;
FICARRA, C ;
HOGAN, EL ;
CARTER, T ;
GURECKI, P ;
MUNTZ, BK ;
RAMIREZLASSEPAS, M ;
TULLOCH, JW ;
QUINONES, MR ;
MENDEZ, M ;
ZHANG, SM ;
ALA, T ;
JOHNSTON, KC ;
ANDERSON, DC ;
TARREL, RM ;
NANCE, MA ;
BUDLIE, SR ;
DIERICH, M ;
HELGASON, CM ;
HIER, DB ;
SHAPIRO, RA .
STROKE, 1993, 24 (01) :35-41
[2]   NPC1: Complete genomic sequence, mutation analysis, and characterization of haplotypes [J].
Bauer, P ;
Knoblich, R ;
Bauer, C ;
Finckh, U ;
Hufen, A ;
Kropp, J ;
Braun, S ;
Kustermann-Kuhn, B ;
Schmidt, D ;
Harzer, K ;
Rolfs, A .
HUMAN MUTATION, 2002, 19 (01) :30-38
[3]   ISCHEMIC STROKE IN PATIENTS UNDER AGE 45 [J].
BOGOUSSLAVSKY, J ;
PIERRE, P .
NEUROLOGIC CLINICS, 1992, 10 (01) :113-124
[4]   Clinical features of and recent advances in therapy for Fabry disease [J].
Brady, RO ;
Schiffmann, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (21) :2771-2775
[5]   Cerebral infarction in young adults - The Baltimore-Washington cooperative young stroke study [J].
Kittner, SJ ;
Stern, BJ ;
Wozniak, M ;
Buchholz, DW ;
Earley, CJ ;
Feeser, BR ;
Johnson, CJ ;
Macko, RF ;
McCarter, RJ ;
Price, TR ;
Sherwin, R ;
Sloan, MA ;
Wityk, RJ .
NEUROLOGY, 1998, 50 (04) :890-894
[6]   Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry [J].
Mills, K ;
Johnson, A ;
Winchester, B .
FEBS LETTERS, 2002, 515 (1-3) :171-176
[7]   Comparison of fluorescent SSCP and denaturing HPLC analysis with direct sequencing for mutation screening in hypertrophic cardiomyopathy [J].
Mogensen, J ;
Bahl, A ;
Kubo, T ;
Elanko, N ;
Taylor, R ;
McKenna, WJ .
JOURNAL OF MEDICAL GENETICS, 2003, 40 (05)
[8]   Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease - Reversal by enzyme replacement therapy [J].
Moore, DF ;
Scott, LTC ;
Gladwin, MT ;
Altarescu, G ;
Kaneski, C ;
Suzuki, K ;
Pease-Fye, M ;
Ferri, R ;
Brady, RO ;
Herscovitch, P ;
Schiffmann, R .
CIRCULATION, 2001, 104 (13) :1506-1512